Lower Lead Limits For Calcium-Containing Products Shelved By FDA
This article was originally published in The Tan Sheet
Executive Summary
FDA is not adopting new, lower lead limits for calcium-containing supplements and antacids at this time but "is actively investigating the feasibility of establishing lower limits," the agency tells the Council for Responsible Nutrition and the Consumer Healthcare Products Association in a Sept. 28 letter.
You may also be interested in...
Calcium Supplementation May Benefit Lead Levels - JAMA Editorial
Calcium intake impedes lead absorption and stops the body from accessing lead deposits in bones, Robert Heaney, MD, maintains in an editorial response to a study on lead content in calcium supplements.
USP Supplement Potency Lower Limit Of 90% Retained
The lower potency limit dietary supplements are required to meet for the duration of their shelf life will remain at 90% of the labeled amount, the U.S. Pharmacopeia Subcommittee on Non Prescription Drugs and Nutritional Supplements voted Dec. 8 in Rockville, Md.
Calcium lead limit sought by NRDC "not scientifically defensible" or "feasible," FDA told.
CALCIUM LEAD LIMIT REQUESTED BY NRDC "NOT SCIENTIFICALLY DEFENSIBLE" or "commercially feasible," the Council for Responsible Nutrition and Nonprescription Drug Manufacturers Association argue in a June 10 joint citizen petition to FDA. The filing responds to the January petition by the Natural Resources Defense Council seeking an FDA-established upper limit of .5 mcg of lead per maximum recommended daily dosage for calcium supplements and antacid products ("The Tan Sheet" Feb. 3, p. 9). The .5 mcg/day level is based on California's Proposition 65 limit for lead.